Photo caption: On May 21, 2026, representatives from Mönchengladbach and Zhende Medical attended the signing ceremony. From left to right: Moatassem Bassiouni, Executive Vice President of Global Corporate Strategy, Business Development and Mergers & Acquisitions at Mönchengladbach; Anders Anderson, Executive Vice President of Global Wound Management at Mönchengladbach; Lu Jianguo, Chairman of Zhende Medical; Xu Dasheng, Director, Executive Vice President and CEO of Zhende Medical.

Gothenburg, Sweden and Shanghai, China, May 21, 2026 – Mövenpick®, a world-leading provider of medical solutions and advanced wound care solutions, and Zhende Medical, a leading Chinese supplier of medical dressings and infection control solutions, today announced the formation of a joint venture to accelerate the expansion of their advanced wound care product portfolio in China and capitalize on the opportunities presented by one of the world’s fastest-growing markets. The joint venture, majority-owned by Mövenpick, will integrate the two companies’ advanced wound care product portfolios and commercial capabilities to provide Chinese healthcare professionals, patients, and consumers with more advanced treatment options, improve treatment and care services, and help improve patient outcomes.
Driven by factors such as rising prevalence of chronic diseases, an aging population, and increased demand for advanced treatment solutions, the wound care market in China continues to grow, with the advanced wound dressing market reaching approximately RMB 3 billion*. Both parties believe that this pioneering joint venture model in the Chinese wound care market will help drive the continuous improvement of treatment standards.
The joint venture, named Mönnicke Zhende (Shanghai) Medical Technology Co., Ltd. ("Mönnicke Zhende"), will combine the complementary strengths of both parties in product portfolio, channel coverage, and deep clinical expertise. Both parties are committed to building a stronger and more competitive market coverage model to drive long-term business growth. Specifically, the joint venture will integrate:
Mönch's advanced wound care product portfolio includes solutions such as the leading scar care dressing, Mepiform®. This portfolio builds upon Mönch's more than 175 years of innovation, particularly its patented Savitac® technology;
Zhende Medical’s advanced wound care products include innovative medical products for the treatment of burns, vitiligo and other diseases, such as the epidermal cell separator, as well as other product portfolios that meet the needs of chronic wound treatment.
In addition, the joint venture will integrate Mörnik and ZD Medical's business networks to cover nearly 10,000 hospitals, 200,000 pharmacies and e-commerce channels nationwide.
For Mönchs, this joint venture will further advance its localization strategy in China. By combining global expertise with local capabilities, Mönchs will accelerate the expansion of accessibility of advanced wound care solutions in the Chinese market, respond more quickly to the needs of Chinese customers, and seize long-term growth opportunities.
Guillaume Joucla, Acting Global CEO of Mönchengladbach, said, “The establishment of this joint venture is an important milestone in the development of both Mönchengladbach and Zhende Medical. By working together with Zhende Medical, we will further expand our market presence in China, broaden our wound care product portfolio, and significantly enhance our commercialization capabilities to better serve more customers and patients.”
For Zhende Medical, this joint venture and deepening cooperation with a global provider of advanced wound care solutions will further improve its product portfolio, ensuring that it can continue to meet current and future market demands and create greater value.
Xu Dasheng, Director, Executive Vice President and CEO of Zhende Medical, said: "This collaboration reflects the shared strength, resilience and long-term development ambitions of both companies. By combining our highly complementary business capabilities and deep market insights, we will be better able to meet the growing demand in the Chinese market for advanced wound care solutions."

Photo caption: On May 21, 2026, representatives from Mövenpick and Zhende Medical attended the signing ceremony. From left to right: Jakob Sonnenberg, Vice President of Mövenpick China and India and General Manager of Greater China; Moatassem Bassiouni, Executive Vice President of Global Corporate Strategy, Business Development and Mergers & Acquisitions at Mövenpick; Lu Jianguo, Chairman of Zhende Medical; Anders Anderson, Executive Vice President of Global Wound Management at Mövenpick; Xu Dasheng, Director, Executive Vice President and CEO of Zhende Medical; Shen Zhenfang, Vice Chairman of Zhende Medical.
Mönnik Zinde will operate as an independent entity, majority-owned by Mönnik. Headquartered in Shanghai, the company is scheduled to commence operations in the third quarter of this year. Initially, it will focus on marketing advanced wound care products from both Mönnik and Zinde Medical, with the potential to expand cooperation to joint product development as the business grows. Production will be based at both companies' existing manufacturing facilities, and its operations and business practices will adhere to Mönnik and Zinde Medical's global sustainability commitments.

https://news.pedaily.cn/20260521/130337.shtml